Well, weight loss patients have five chief complaints: Tolerability - GLP-1s can induce GI side-effects, like nausea and vomiting Durability - once GLP-1 therapy is discontinued, patients regain weight Frequency - most GLP-1s are administered sub-cutaneously every week Access - Medicare, Medicaid, and most commercial insurers dont cover GLP-1s for weight loss
Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
If you miss your scheduled day by 1-2 days, inject as soon as you remember and then resume your regular schedule the following week
On July 10, 2024, Kuei-Pin Huang and colleagues published a paper in Nature titled Dissociable Hindbrain GLP1R Circuits for Satiety and Aversion. The study suggests that future weight loss medications could selectively target GLP1R neurons in the nucleus of the solitary tract (NTS) to avoid inducing aversion, thereby improving treatment adherence and effectiveness [1]